RESUMO

Background: COVID-19 survivors who were hospitalised continue to experience long-term multisystemic sequelae and symptoms, impacting their health-related quality of life (HRQoL). The complexity of post-COVID-19 conditions underscores the importance of adopting a multidisciplinary, patient-centric approach to ensure ongoing care. This study aims to assess HRQoL and post-COVID symptoms in a cohort of severe COVID-19 survivors depending on their participation in a multidisciplinary programme. Methods: This prospective study was conducted in a post-COVID clinic staffed by a multidisciplinary team (physical rehabilitator, nutritionist, psychologist, including experts in pulmonary rehabilitation, nutrition, psychology and others). Subjects over 18 years old who were hospitalised due to severe COVID-19 during the acute phase and had attended the post-COVID clinic within the first 3 months following discharge were included. Subjects who were unable or unwilling to provide informed consent to participate in the protocol were excluded. Linear mixed-effect models were employed to examine changes in 12-Item Short-Form Health Survey (SF-12) component scores. The resolution of post-COVID symptom clusters was compared using the Cox model. Results: A total of 730 patients were included, with a mean±sd age of 55.78±15.43 years; 60.55% were male and 90.62% required mechanical ventilation during hospitalisation. Programme attendants demonstrated improved SF-12 physical and mental component scores at 3 and 12 months. A reduction in the prevalence of post-COVID symptoms was observed in both groups, with greater reductions in those attending the programme. Conclusion: Our study showed that patients enrolled on the multidisciplinary programme experienced improvements in fatigue, musculoskeletal, gastrointestinal, neuropsychiatric and respiratory symptoms, along with enhanced SF-12 mental and physical component scores.

RESUMO

Background: Lung cancer represents a significant global health concern, often diagnosed in its advanced stages. The advent of massive DNA sequencing has revolutionized the landscape of cancer treatment by enabling the identification of target mutations and the development of tailored therapeutic approaches. Unfortunately, access to DNA sequencing technology remains limited in many developing countries. In this context, we emphasize the critical importance of integrating this advanced technology into healthcare systems in developing nations to improve treatment outcomes. Methods: We conducted an analysis of electronic clinical records of patients with confirmed advanced non-small cell lung cancer (NSCLC) and a verified negative status for the epidermal growth factor receptor (EGFR) mutation. These patients underwent next-generation sequencing (NGS) for molecular analysis. We performed descriptive statistical analyses for each variable and conducted both univariate and multivariate statistical analyses to assess their impact on progression-free survival (PFS) and overall survival (OS). Additionally, we classified genetic mutations as actionable or non-actionable based on the European Society for Medical Oncology Scale of Clinical Actionability of Molecular Targets (ESCAT) guidelines. Results: Our study included a total of 127 patients, revealing the presence of twenty-one distinct mutations. The most prevalent mutations were EGFR (18.9%) and Kirsten rat sarcoma viral oncogene homolog (KRAS) (15.7%). Notably, anaplastic lymphoma kinase (ALK) [hazard ratio (HR): 0.258, P<0.001], tumor mutation burden (TMB) (HR: 2.073, P=0.042) and brain magnetic resonance imaging (MRI) (HR: 0.470, P=0.032) demonstrated statistical significance in both the univariate and multivariate analyses with respect to PFS. In terms of OS, ALK (HR: 0.285, P<0.001) and EGFR (HR: 0.482, P=0.024) exhibited statistical significance in both analyses. Applying the ESCAT classification system, we identified actionable genomic variations (ESCAT level-1), including EGFR, ALK, breast cancer (BRAF) gene, c-ros oncogene 1 (ROS1), and rearranged during transfection (RET) gene, in 32.3% of the patients. Conclusions: Our findings from massive DNA sequencing underscore that 32.3% of patients who test negative for the EGFR mutation possess other targetable mutations, enabling them to receive personalized, targeted therapies at an earlier stage of their disease. Implementing massive DNA sequencing in developing countries is crucial to enhance survival rates among NSCLC patients and guide more effective treatment strategies.

Assuntos

RESUMO

There is still a need for safe, efficient, and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we evaluated a vaccine candidate based on a live recombinant Newcastle disease virus (NDV) that expresses a stable version of the spike protein in infected cells as well as on the surface of the viral particle (AVX/COVID-12-HEXAPRO, also known as NDV-HXP-S). This vaccine candidate can be grown in embryonated eggs at a low cost, similar to influenza virus vaccines, and it can also be administered intranasally, potentially to induce mucosal immunity. We evaluated this vaccine candidate in prime-boost regimens via intramuscular, intranasal, or intranasal followed by intramuscular routes in an open-label non-randomized non-placebo-controlled phase I clinical trial in Mexico in 91 volunteers. The primary objective of the trial was to assess vaccine safety, and the secondary objective was to determine the immunogenicity of the different vaccine regimens. In the interim analysis reported here, the vaccine was found to be safe, and the higher doses tested were found to be immunogenic when given intramuscularly or intranasally followed by intramuscular administration, providing the basis for further clinical development of the vaccine candidate. The study is registered under ClinicalTrials.gov identifier NCT04871737.

RESUMO

PURPOSE: Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios. Our goal is to provide insights of a three-drug chemotherapy regimen improving patient survival compared to standard regimens. METHODS: Retrospective cohort analysis of patients diagnosed with unresectable/advanced primary thoracic sarcoma divided between primary pulmonary sarcomas (PPS) and chest wall sarcomas (CWS) comparing chemotherapeutical regimens efficacy. Not true soft tissue sarcomas (STS) for PPS were excluded from the analysis. Univariate and multivariate analysis performed via Cox-regression model. Progression-free survival (PFS) and overall survival (OS) analysis via Kaplan-Meier with hazard ratio (HR) obtained via Mantel-Haenszel or log rank. RESULTS: 157 total cases were included, from which 50 cases were PPS and 107 cases CWS. For PPS, 4 cases were excluded from the analysis as they were not true STS. The most common histology was undifferentiated sarcomas, 63% of cases were treated with E/C/I and 37% with another regimen. The E/C/I regimen demonstrated a benefit for both OS (p = 0.020) and PFS (p = 0.010) when compared to any other regimen as well as when compared to non-platinum regimens (p = 0.016 and p = 0.001). Regarding CWS, the most common histology was synovial and undifferentiated sarcomas, 55.1% were treated with E/C/I and 44.9% treated with another regimen. The E/C/I regimen did not demonstrate a benefit for OS or PFS compared to any other regimen, neither when compared to other non-platinum regimens. However, a benefit was observed in favor of E/C/I when compared to other platinum regimens in both OS (p = 0.049) and PFS (0.015). Both analyses for PPS and CWS demonstrated a benefit in favor of cisplatin therapies compared to carboplatin in both OS and PFS. CONCLUSION: This study demonstrates that platinum therapy alone does not work, and that cisplatin must be the agent of choice and it's used in combination could increase treatment response. The E/C/I regimen demonstrated a in PPS but not for CWS, this is due do their rarity of PPS and that no standard treatment is established yet. The regimen proposed here could represent a possible new standard of treatment for PPS as long as it is validated in a prospective study.

Assuntos

RESUMO

INTRODUCTION: For many patients, organ transplantation is the only life-saving treatment. There is a severe shortage of organs for transplantation, and Mexico has one of the lowest organ donation rates. Health professionals are the link between society and the health system, and can promote and increase organ donation. OBJECTIVE: To explore general knowledge and attitudes of Mexican physicians with regard to cadaveric organ donation. METHODS: Cross-sectional, observational study. Two questionnaires were applied to 219 physicians either from an institution where transplants are carried out or from a hospital where the procedure is not performed. RESULTS: Most participants had not received any training on organ donation. The main deficits in their knowledge were related to the criteria for being a donor and to the position of the Church on organ donation. Knowledge predicted attitudes towards organ donation: it was negatively associated with unfavorable and mistrust attitudes, whereas it was positively associated with favorable attitudes and willingness to be a donor. CONCLUSION: It is necessary to implement programs aimed at physicians in order to provide them with tools that help promote organ donation culture.

INTRODUCCIÓN: Para numerosos pacientes, el trasplante de órganos es el único tratamiento para sobrevivir. Hay una grave escasez de órganos para trasplantes y México tiene una de las tasas más bajas de donación de órganos. Los profesionales de la salud son el vínculo entre la sociedad y el sistema de salud, y pueden promover e incrementar la donación de órganos. OBJETIVO: Explorar los conocimientos generales y las actitudes de médicos mexicanos respecto a la donación de órganos provenientes de cadáveres. MÉTODOS: Estudio observacional transversal. Se aplicaron dos cuestionarios a 219 médicos de una institución donde se realizan trasplantes y de un hospital en donde no se llevan a cabo. RESULTADOS: La mayoría de los participantes no había recibido entrenamiento sobre donación de órganos. Las principales deficiencias en sus conocimientos estuvieron relacionadas con los criterios para ser donador y la postura de la iglesia sobre la donación de órganos. El conocimiento predijo las actitudes hacia la donación de órganos; este se asoció negativamente a actitudes desfavorables y de desconfianza, mientras que se asoció positivamente a actitudes favorables y la disposición a ser donador. CONCLUSIÓN: Es necesario implementar programas dirigidos a los médicos para dotarlos de herramientas que ayuden a fomentar la cultura de donación de órganos.

Assuntos

RESUMO

Background: Primary thoracic sarcomas (PTS) including primary pulmonary and chest wall sarcomas (CWS), are aggressive lung malignancies with limited information specially in an advanced/unresectable setting. Unfortunately, prognostic factors for these malignancies are not well identified. Methods: Retrospective cohort analysis of patients diagnosed with unresectable/advanced soft tissue PTS from a third level reference institute. Univariate and multivariate analysis performed via Cox-regression model. Progression-free survival (PFS) and overall survival (OS) analysis via Kaplan-Meier method. Results: A total of 157 patients were identified, 55.4% female, mean age 51.8 years (range, 18-90 years), 19.1% tobacco exposure and 10.8% asbestos exposure. The most common performance status was Eastern Cooperative Oncology Group (ECOG) 1 (38.9%), most common clinical presentation cough (58.4%) and thoracic pain (55.4%). Undifferentiated sarcoma (37.6%) followed by synovial sarcoma (34.4%) were the most common histologies. Most patients received five chemotherapeutic cycles (37.6%), 57.3% of patients obtained a partial response and 61.1% an overall response rate (ORR). Median PFS was 9 months [95% confidence interval (CI): 8.717-9.283 months]. The multivariable analysis identified ECOG ≥2, a poorer response to chemotherapy (less number of chemotherapy cycles) and an increase Response Evaluation Criteria in Solid Tumors (RECIST) to be associated with a shorter progression-free period. Median OS was 11 months (95% CI: 10.402-11.958 months) with an ECOG ≥2 and a poorer response to chemotherapy (less number of chemotherapy cycles) associated with a shorter survival. Conclusions: Age, gender, comorbidities, tobacco and asbestos exposure, clinical presentation and histopathological diagnosis are not useful prognostic factors in unresectable/advanced PTS, however, an adequate initial ECOG, RECIST and a better response to chemotherapy should be used as prognostic factors in the management of these tumors.

RESUMO

Resumen Introducción: Para numerosos pacientes, el trasplante de órganos es el único tratamiento para sobrevivir. Hay una grave escasez de órganos para trasplantes y México tiene una de las tasas más bajas de donación de órganos. Los profesionales de la salud son el vínculo entre la sociedad y el sistema de salud, y pueden promover e incrementar la donación de órganos. Objetivo: Explorar los conocimientos generales y las actitudes de médicos mexicanos respecto a la donación de órganos provenientes de cadáveres. Métodos: Estudio observacional transversal. Se aplicaron dos cuestionarios a 219 médicos de una institución donde se realizan trasplantes y de un hospital en donde no se llevan a cabo. Resultados: La mayoría de los participantes no había recibido entrenamiento sobre donación de órganos. Las principales deficiencias en sus conocimientos estuvieron relacionadas con los criterios para ser donador y la postura de la iglesia sobre la donación de órganos. El conocimiento predijo las actitudes hacia la donación de órganos; este se asoció negativamente a actitudes desfavorables y de desconfianza, mientras que se asoció positivamente a actitudes favorables y la disposición a ser donador. Conclusión: Es necesario implementar programas dirigidos a los médicos para dotarlos de herramientas que ayuden a fomentar la cultura de donación de órganos.

Abstract Introduction: For many patients, organ transplantation is the only life-saving treatment. There is a severe shortage of organs for transplantation, and Mexico has one of the lowest organ donation rates. Health professionals are the link between society and the health system, and can promote and increase organ donation. Objective: To explore general knowledge and attitudes of Mexican physicians with regard to cadaveric organ donation. Methods: Cross-sectional, observational study. Two questionnaires were applied to 219 physicians either from an institution where transplants are carried out or from a hospital where the procedure is not performed. Results: Most participants had not received any training on organ donation. The main deficits in their knowledge were related to the criteria for being a donor and to the position of the Church on organ donation. Knowledge predicted attitudes towards organ donation: it was negatively associated with unfavorable and mistrust attitudes, whereas it was positively associated with favorable attitudes and willingness to be a donor. Conclusion: It is necessary to implement programs aimed at physicians in order to provide them with tools that help promote organ donation culture.

RESUMO

There is still a need for safe, efficient and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we evaluated a vaccine candidate based on a live recombinant Newcastle disease virus (NDV) that expresses a stable version of the spike protein in infected cells as well as on the surface of the viral particle (AVX/COVID-12-HEXAPRO, also known as NDV-HXP-S). This vaccine candidate can be grown in embryonated eggs at low cost similar to influenza virus vaccines and it can also be administered intranasally, potentially to induce mucosal immunity. We evaluated this vaccine candidate in prime-boost regimens via intramuscular, intranasal, or intranasal followed by intramuscular routes in an open label non-randomized non-placebo-controlled phase I clinical trial in Mexico in 91 volunteers. The primary objective of the trial was to assess vaccine safety and the secondary objective was to determine the immunogenicity of the different vaccine regimens. In the interim analysis reported here, the vaccine was found to be safe and the higher doses tested were found to be immunogenic when given intramuscularly or intranasally followed by intramuscular administration, providing the basis for further clinical development of the vaccine candidate. The study is registered under ClinicalTrials.gov identifier NCT04871737. Funding was provided by Avimex and CONACYT.